Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection
Floriane Gallais(Inserm), Samira Fafi‐Kremer(Centre National de la Recherche Scientifique), Aurélie Velay(Hôpitaux Universitaires de Strasbourg), Timothée Bruel(Institut Pasteur), Sophie Bayer, Nathalie Reix, Pierre Gantner(Inserm), Delphine Planas(Centre Hospitalier de l’Université de Montréal), Catherine Schmidt‐Mutter(Inserm), Baptiste Panaget(Inserm), Yves Hansmann(Hôpitaux Universitaires de Strasbourg), Arnaud Fontanet(Institut Pasteur), Olivier Schwartz(Centre National de la Recherche Scientifique), Morgane Solis(Inserm), Laurence Kling-Pillitteri, Nicolas Collongues(Inserm), Ludovic Glady, Maria Gonzalez, Anne Schneider, David Rey, Nicolás Meyer, Marialuisa Partisani, Jean‐Marc Lessinger, de Sèze(Hôpital d'Hautepierre), Marie-Josée Wendling(Institut de Virologie), Elodie Laugel(Inserm)
Cited by 239
Related Papers
International consensus diagnostic criteria for neuromyelitis optica spectrum disorders
|Neurology|2015|4.6k
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis
|New England Journal of Medicine|2016|1.9k
MOG encephalomyelitis: international recommendations on diagnosis and antibody testing
|Journal of Neuroinflammation|2018|740
Ofatumumab versus Teriflunomide in Multiple Sclerosis
|New England Journal of Medicine|2020|706
Neuromyelitis Optica and Non–Organ-Specific Autoimmunity
|Archives of Neurology|2008|612